Adlai shares surge 13.35% intraday after securing $140M private equity financing led by Cormorant Asset Management and Columbia Threadneedle Investments to accelerate RAS-targeted cancer therapies.

Adlai surged 13.35% intraday, as the company announced a $140 million private equity financing led by Cormorant Asset Management and Columbia Threadneedle Investments, enhancing its financial strength and accelerating the development of RAS-targeted cancer therapies. The company is a clinical-stage biotechnology firm focused on developing innovative cancer treatments.